Therefore, we tested the hypothesis that EPA decreases plasma and tissue CCL2 levels in pre-clinical rodent CRC models and samples from the RCT of EPA in CRCLM patients (The EMT study). The gene discussed is CCL2; the disease is colorectal carcinoma.